SWK (SWKH) 10-Q 12 Aug 19 2019 Q2 Quarterly report Financial data

Document and Entity Information

Document and Entity Information - shares	6 Months Ended
	Jun. 30, 2019	Aug. 12, 2019
Cover [Abstract]
Document Type	10-Q
Amendment Flag	false
Document Period End Date	Jun. 30, 2019
Current Fiscal Year End Date	--12-31
Entity File Number	000-27163
Entity Registrant Name	SWK Holdings Corp
Entity Central Index Key	0001089907
Entity Tax Identification Number	77-0435679
Entity Incorporation, State or Country Code	DE
Entity Address, Address Line One	14755 Preston Road
Entity Address, Address Line Two	Suite 105
Entity Address, City or Town	Dallas
Entity Address, State or Province	TX
Entity Address, Postal Zip Code	75254
City Area Code	972
Local Phone Number	687-7250
Entity Current Reporting Status	Yes
Entity Interactive Data Current	Yes
Entity Filer Category	Non-accelerated Filer
Entity Small Business	true
Entity Emerging Growth Company	false
Elected Not To Use the Extended Transition Period	false
Entity Common Stock, Shares Outstanding		12,904,346
Document Fiscal Period Focus	Q2
Document Fiscal Year Focus	2019

UNAUDITED CONDENSED CONSOLIDATE

UNAUDITED CONDENSED CONSOLIDATED BALANCE SHEETS - USD ($) $ in Thousands	Jun. 30, 2019	Dec. 31, 2018
ASSETS
Cash and cash equivalents	$ 27,373	$ 20,227
Accounts receivable	2,179	2,195
Finance receivables, net	169,156	166,610
Marketable investments	498	532
Deferred tax asset	20,899	22,684
Warrant assets	3,993	2,777
Other assets	570	637
Total assets	224,668	215,662
Commitments and contingencies
LIABILITIES AND STOCKHOLDERS' EQUITY
Accounts payable and accrued liabilities	1,305	2,592
Warrant liability	28	13
Total liabilities	1,333	2,605
Stockholders' equity:
Preferred stock, $0.001 par value; 5,000,000 shares authorized; no shares issued and outstanding as of June 30, 2019 and December 31, 2018, respectively
Common stock, $0.001 par value; 250,000,000 shares authorized; 12,904,399 and 12,933,674 shares issued and outstanding as of June 30, 2019 and December 31, 2018, respectively	13	13
Additional paid-in capital	4,431,891	4,432,499
Accumulated deficit	(4,208,569)	(4,219,455)
Total SWK Holdings Corporation stockholders' equity	223,335	213,057
Total liabilities and stockholders' equity	$ 224,668	$ 215,662

UNAUDITED CONDENSED CONSOLIDA_2

UNAUDITED CONDENSED CONSOLIDATED BALANCE SHEETS (Parenthetical) - $ / shares	Jun. 30, 2019	Dec. 31, 2018
Statement of Financial Position [Abstract]
Preferred stock, par value (in dollars per share)	$ 0.001	$ 0.001
Preferred stock, authorized	5,000,000	5,000,000
Preferred stock, issued	0	0
Preferred stock, outstanding	0	0
Common stock, par value (in dollars per share)	$ 0.001	$ 0.001
Common stock, authorized	250,000,000	250,000,000
Common stock, issued	12,904,399	12,933,674
Common stock, outstanding	12,904,399	12,933,674

UNAUDITED CONDENSED CONSOLIDA_3

UNAUDITED CONDENSED CONSOLIDATED STATEMENTS OF INCOME - USD ($) $ in Thousands	3 Months Ended		6 Months Ended
	Jun. 30, 2019	Jun. 30, 2018	Jun. 30, 2019	Jun. 30, 2018
Revenues
Finance receivable interest income, including fees	$ 5,654	$ 6,764	$ 15,045	$ 13,581
Other	1	3	2	7
Revenues	5,655	6,767	15,047	13,588
Costs and expenses:
Provision for loan credit losses			609	1,179
Interest expense	78	2	180	2
General and administrative	1,324	1,176	2,593	2,397
Total costs and expenses	1,402	1,178	3,382	3,578
Other income (expense), net
Unrealized net gain on warrants	748	(238)	1,006	61
Unrealized net loss on equity securities		(541)		(664)
Income before provision for income taxes	5,001	4,810	12,671	9,407
Provision (benefit) for income taxes	674	1,142	1,785	2,095
Consolidated net income	$ 4,327	$ 3,668	$ 10,886	$ 7,312
Net income (loss) per share attributable to SWK Holdings Corporation Stockholders
Basic (in dollars per share)	$ 0.34	$ 0.28	$ 0.84	$ 0.56
Diluted (in dollars per share)	$ 0.34	$ 0.28	$ 0.84	$ 0.56
Weighted Average Shares
Basic (in shares)	12,900,000	13,059,000	12,903,000	13,056,000
Diluted (in shares)	12,903,000	13,063,000	12,906,000	13,060,000

UNAUDITED CONDENSED CONSOLIDA_4

UNAUDITED CONDENSED CONSOLIDATED STATEMENTS OF COMPREHENSIVE INCOME - USD ($) $ in Thousands	3 Months Ended		6 Months Ended
	Jun. 30, 2019	Jun. 30, 2018	Jun. 30, 2019	Jun. 30, 2018
Statement of Comprehensive Income [Abstract]
Consolidated net income	$ 4,327	$ 3,668	$ 10,886	$ 7,312
Other comprehensive income (loss), net of tax
Other comprehensive income, net of tax
Comprehensive income	$ 4,327	$ 3,668	$ 10,886	$ 7,312

UNAUDITED CONDENSED CONSOLIDA_5

UNAUDITED CONDENSED CONSOLIDATED STATEMENTS OF STOCKHOLDERS' EQUITY (Unaudited) - USD ($) $ in Thousands	Common Stock	Additional Paid-In Capital	Accumulated Deficit	Accumulated Other Comprehensive Income	Total
Beginning Balance at Dec. 31, 2017	$ 13	$ 4,433,589	$ (4,225,863)	$ 213	$ 207,952
Beginning Balance, in Shares at Dec. 31, 2017	13,053,422
Stock-based compensation		79			79
Issuance of common stock
Issuance of common stock, in Shares	5,768
Cumulative effect of adoption of New Accounting Principles			213	(213)
Net income			3,644		3,644
Ending Balance at Mar. 31, 2018	$ 13	4,433,668	(4,222,006)		211,675
Ending Balance, in Shares at Mar. 31, 2018	13,059,190
Beginning Balance at Dec. 31, 2017	$ 13	4,433,589	(4,225,863)	213	207,952
Beginning Balance, in Shares at Dec. 31, 2017	13,053,422
Stock-based compensation					140
Net income					7,312
Ending Balance at Jun. 30, 2018	$ 13	4,433,729	(4,218,338)		215,404
Ending Balance, in Shares at Jun. 30, 2018	13,063,915
Beginning Balance at Mar. 31, 2018	$ 13	4,433,668	(4,222,006)		211,675
Beginning Balance, in Shares at Mar. 31, 2018	13,059,190
Stock-based compensation		61			61
Issuance of common stock
Issuance of common stock, in Shares	4,725
Net income			3,668		3,668
Ending Balance at Jun. 30, 2018	$ 13	4,433,729	(4,218,338)		215,404
Ending Balance, in Shares at Jun. 30, 2018	13,063,915
Beginning Balance at Dec. 31, 2018	$ 13	4,432,499	(4,219,455)		213,057
Beginning Balance, in Shares at Dec. 31, 2018	12,933,674
Stock-based compensation		102			102
Issuance of common stock
Issuance of common stock, in Shares	42,225
Repurchases of common stock in open market		(745)			(745)
Repurchases of common stock in open market (in shares)	(77,300)
Net income			6,559		6,559
Ending Balance at Mar. 31, 2019	$ 13	4,431,856	(4,212,896)		218,973
Ending Balance, in Shares at Mar. 31, 2019	12,898,599
Beginning Balance at Dec. 31, 2018	$ 13	4,432,499	(4,219,455)		213,057
Beginning Balance, in Shares at Dec. 31, 2018	12,933,674
Stock-based compensation					190
Net income					10,886
Ending Balance at Jun. 30, 2019	$ 13	4,431,891	(4,208,569)		223,335
Ending Balance, in Shares at Jun. 30, 2019	12,904,399
Beginning Balance at Mar. 31, 2019	$ 13	4,431,856	(4,212,896)		218,973
Beginning Balance, in Shares at Mar. 31, 2019	12,898,599
Stock-based compensation		88			88
Issuance of common stock
Issuance of common stock, in Shares	11,000
Repurchases of common stock in open market		(53)			(53)
Repurchases of common stock in open market (in shares)	(5,200)
Net income			4,327		4,327
Ending Balance at Jun. 30, 2019	$ 13	$ 4,431,891	$ (4,208,569)		$ 223,335
Ending Balance, in Shares at Jun. 30, 2019	12,904,399

UNAUDITED CONDENSED CONSOLIDA_6

UNAUDITED CONDENSED CONSOLIDATED STATEMENTS OF CASH FLOWS - USD ($) $ in Thousands	6 Months Ended
	Jun. 30, 2019	Jun. 30, 2018
Cash flows from operating activities:
Consolidated net income	$ 10,886	$ 7,312
Adjustments to reconcile net income (loss) to net cash provided by operating activities:
Provision for loan credit losses	609	1,179
Amortization of debt issuance costs	93
Deferred income taxes	1,785	2,095
Change in fair value of warrants	(1,006)	(61)
Change in fair value of equity securities		664
Loan discount amortization and fee accretion	483	(1,727)
Interest paid-in-kind	(805)	(96)
Stock-based compensation	190	140
Interest income in excess of cash collected	(82)	(125)
Other	3	8
Changes in operating assets and liabilities:
Interest receivable	16	53
Other assets	(26)	(19)
Accounts payable and other liabilities	(1,287)	(334)
Net cash provided by operating activities	10,859	9,089
Cash flows from investing activities:
Investment in finance receivables	(33,539)	(46,710)
Repayment of finance receivables	30,590	28,458
Corporate debt security principal payment	34	39
Other		(4)
Net cash provided by (used in) investing activities	(2,915)	(18,217)
Cash flows from financing activities:
Repurchases of common stock, including fees and expenses	(798)
Debt issuance costs		(148)
Net cash used in financing activities	(798)	(148)
Net decrease in cash and cash equivalents	7,146	(9,276)
Cash and cash equivalents at beginning of period	20,227	30,557
Cash and cash equivalents at end of period	$ 27,373	$ 21,281

SWK Holdings Corporation and Su

SWK Holdings Corporation and Summary of Significant Accounting Policies	6 Months Ended
	Jun. 30, 2019
Accounting Policies [Abstract]
SWK Holdings Corporation and Summary of Significant Accounting Policies	Note 1. SWK Holdings Corporation and Summary of Significant Accounting Policies Nature of Operations SWK Holdings Corporation (the “Company”) was incorporated in July 1996 in California and reincorporated in Delaware in September 1999. In July 2012, the Company commenced its strategy of building a specialty finance and asset management business. The Company’s strategy is to be a leading healthcare capital provider by offering sophisticated, customized financing solutions to a broad range of life science companies, institutions and inventors. The Company is primarily focused on monetizing cash flow streams derived from commercial-stage products and related intellectual property through royalty purchases and financings, as well as through the creation of synthetic revenue interests in commercialized products. The Company has been deploying its assets to earn interest, fees, and other income pursuant to this strategy, and the Company continues to identify and review financing and similar opportunities on an ongoing basis. In addition, through the Company’s wholly-owned subsidiary, SWK Advisors LLC, the Company provides non-discretionary investment advisory services to institutional clients in separately managed accounts to similarly invest in life science finance. SWK Advisors LLC is registered as an investment advisor with the Texas State Securities Board. The Company intends to fund transactions through its own working capital, and its revolving credit facility, as well as by building its asset management business by raising additional third-party capital to be invested alongside the Company’s capital. The Company fills a niche that it believes is underserved in the sub-$50 million transaction size. Since many of its competitors that provide longer term, non-traditional debt and/or royalty-related financing options have much greater financial resources than the Company, they tend to not focus on transaction sizes below $50 million as it is generally inefficient for them to do so. In addition, the Company does not believe that a sufficient number of other companies offer similar types of long-term financing options to fill the demand of the sub-$50 million market. As such, the Company believes it faces less competition from such investors in transactions that are less than $50 million. The Company has net operating loss carryforwards (“NOLs”) and believes that the ability to utilize these NOLs is an important and substantial asset. However, at this time, under current law, we do not anticipate that our life science business strategy will generate sufficient income to permit us to utilize all of our NOLs prior to their respective expiration dates. As such, it is possible that we might pursue additional strategies that we believe might result in our ability to utilize more of our NOLs. As of August 12, 2019, the Company and its partners have executed transactions with 35 different parties under its specialty finance strategy, funding an aggregate $516 million in various financial products across the life science sector. The Company’s portfolio includes senior and subordinated debt backed by royalties and synthetic royalties paid by companies in the life science sector, and purchased royalties generated by sales of life science products and related intellectual property. The Company is headquartered in Dallas, Texas. Basis of Presentation and Principles of Consolidation The Company’s consolidated financial statements are prepared in accordance with accounting principles generally accepted in the U.S. (“GAAP”). The consolidated financial statements include the accounts of all subsidiaries and affiliates in which the Company holds a controlling financial interest as of the financial statement date. Normally a controlling financial interest reflects ownership of a majority of the voting interests. The Company consolidates a variable interest entity (“VIE”) when it possesses both the power to direct the activities of the VIE that most significantly impact its economic performance and the Company is either obligated to absorb the losses that could potentially be significant to the VIE or the Company holds the right to receive benefits from the VIE that could potentially be significant to the VIE, after elimination of intercompany accounts and transactions. The Company owns interests in various partnerships and limited liability companies, or LLCs. The Company consolidates its investments in these partnerships or LLCs, where the Company, as the general partner or managing member, exercises effective control, even though the Company’s ownership may be less than 50 percent, the related governing agreements provide the Company with broad powers, and the other parties do not participate in the management of the entities and do not effectively have the ability to remove the Company. The Company has reviewed each of the underlying agreements to determine if it has effective control. If circumstances change and it is determined this control does not exist, any such investment would be recorded using the equity method of accounting. Although this would change individual line items within the Company’s consolidated financial statements, it would have no effect on its operations and/or total stockholders’ equity attributable to the Company. Unaudited Interim Financial Information The unaudited condensed consolidated financial statements have been prepared by the Company and reflect all normal, recurring adjustments that, in the opinion of management, are necessary for a fair presentation of the interim financial information. The results of operations for the interim periods presented are not necessarily indicative of the results to be expected for any subsequent quarter or for the year ending December 31, 2019. Certain information and footnote disclosures normally included in financial statements prepared in accordance with GAAP have been condensed or omitted under the rules and regulations of the Securities and Exchange Commission (“SEC”). These unaudited condensed consolidated financial statements and notes included herein should be read in conjunction with the audited consolidated financial statements and notes included in the Company’s Annual Report on Form 10-K for the year ended December 31, 2018, filed with the SEC on March 28, 2019. Use of Estimates The preparation of the Company’s consolidated financial statements in conformity with GAAP requires the Company to make estimates and assumptions that affect the reported amounts of assets and liabilities at the date of the consolidated financial statements and the reported amounts of revenues and expenses during the reporting period. Significant estimates and assumptions are required in the determination of revenue recognition, stock-based compensation, impairment of financing receivables and long-lived assets, valuation of warrants, income taxes and contingencies and litigation, among others. Some of these judgments can be subjective and complex, and consequently, actual results may differ from these estimates. The Company’s estimates often are based on complex judgments, probabilities and assumptions that it believes to be reasonable but that are inherently uncertain and unpredictable. For any given individual estimate or assumption made by the Company, there may also be other estimates or assumptions that are reasonable. The Company regularly evaluates its estimates and assumptions using historical experience and other factors, including the economic environment. As future events and their effects cannot be determined with precision, the Company’s estimates and assumptions may prove to be incomplete or inaccurate, or unanticipated events and circumstances may occur that might cause changes to those estimates and assumptions. Market conditions, such as illiquid credit markets, volatile equity markets, and economic downturns, can increase the uncertainty already inherent in the Company’s estimates and assumptions. The Company adjusts its estimates and assumptions when facts and circumstances indicate the need for change. Those changes generally will be reflected in our consolidated financial statements on a prospective basis unless they are required to be treated retrospectively under the relevant accounting standard. It is possible that other professionals, applying reasonable judgment to the same facts and circumstances, could develop and support a range of alternative estimated amounts. Recent Accounting Pronouncements In August 2018, the Financial Accounting Standards Board (“FASB”) issued Accounting Standards Update (“ASU”) No. 2018-13, “Fair Value Measurement (Topic 820) - Disclosure Framework - Changes to the Disclosure Requirements for Fair Value Measurement.” ASU 2018-13 updates the fair value measurement disclosure requirements by (i) eliminating certain requirements, including disclosure of the amount of and reasons for transfers between Level 1 and Level 2 of the fair value hierarchy, the policy for timing of transfers between levels and the valuation processes for Level 3 fair value measurements, (ii) modifying certain requirements, including clarifying that the measurement uncertainty disclosure is to communicate information about the uncertainty in measurement as of the reporting date and (iii) adding certain requirements, including disclosure of the changes in unrealized gains and losses for the period included in other comprehensive income for recurring Level 3 fair value measurements held at the end of the reporting period and the range and weighted average of significant unobservable inputs used to develop Level 3 fair value measurements. ASU 2018-13 is effective for fiscal years and interim periods within those years beginning after December 15, 2019, with early adoption permitted for any eliminated or modified disclosures. The Company is currently evaluating the new guidance but believes it will not have a material impact on its consolidated financial statements, as the Company has had no historical transfers between hierarchies. In June 2016, the FASB issued ASU No. 2016-13, “Financial Instruments - Credit Losses (Topic 326).” The new standard adds an impairment model, known as the current expected credit loss (“CECL”) model, that is based on expected losses rather than incurred losses. Under the new guidance, an entity recognizes as an allowance its estimate of expected credit losses, which the FASB believes will result in more timely recognition of losses. The ASU describes the impairment allowance as a valuation account that is deducted from the amortized cost basis of the financial asset(s) to present the net carrying value at the amount expected to be collected on the financial asset. Credit losses relating to available-for-sale debt securities should be measured in a manner similar to current GAAP; however, the amendments in this update require that credit losses be presented as an allowance rather than as a write-down, which will allow an entity the ability to record reversals of credit losses in current period net income. The amendments in this update are effective for fiscal years beginning after December 15, 2019, including interim periods within those fiscal years. An entity will apply the amendments in this update through a cumulative-effect adjustment to retained earnings as of the beginning of the first reporting period in which the guidance is effective (that is, a modified-retrospective approach). A prospective transition approach is required for debt securities for which an other-than-temporary impairment has been recognized before the effective date. The Company is currently evaluating the new guidance but believes it is likely to incur more upfront losses on its portfolio under the new CECL model. In February 2016, the FASB issued ASU No. 2016-02, Leases, as amended by subsequent ASUs (Topic 842). ASU 2016-02 supersedes guidance related to accounting for leases and provides for the recognition of lease assets and lease liabilities by lessees for those leases classified as operating leases under previous GAAP. The objective of the ASU is to establish the principles that lessees and lessors shall apply to report useful information to users of financial statements about the amount, timing and uncertainty of cash flows arising from a lease. ASU 2016-02 does not fundamentally change lessor accounting; however, some changes have been made to lessor accounting to conform and align that guidance with the lessee guidance and other areas within GAAP. The ASU is effective for fiscal years and interim periods within those years beginning after December 15, 2018. The Company adopted ASU 2016-02 on January 1, 2019 using the modified retrospective transition method, which permits application of the new standard on the adoption date as opposed to the earliest comparative period presented in the financial statements. In addition, the Company elected to use the available practical expedient package, and therefore did not reassess classification of its existing leases. The adoption of this ASU did not have a material impact on the Company’s consolidated financial statements.

Net Income per Share

Net Income per Share	6 Months Ended
	Jun. 30, 2019
Financial Assets
Net Income per Share	Note 2. Net Income per Share Basic net income per share is computed using the weighted-average number of outstanding shares of common stock. Diluted net income per share is computed using the weighted-average number of outstanding shares of common stock, and when dilutive, shares of common stock issuable upon exercise of options and warrants deemed outstanding using the treasury stock method. The following table shows the computation of basic and diluted net income per share for the following periods (in thousands, except per share amounts): Three Months Ended Six Months Ended 2019 2018 2019 2018 Numerator: Net income $ 4,327 $ 3,668 $ 10,886 $ 7,312 Denominator: Weighted-average shares outstanding 12,900 13,059 12,903 13,056 Effect of dilutive securities 3 4 3 4 Weighted-average diluted shares 12,903 13,063 12,906 13,060 Basic net income per share $ 0.34 $ 0.28 $ 0.84 $ 0.56 Diluted net income per share $ 0.34 $ 0.28 $ 0.84 $ 0.56 For the three months ended June 30, 2019 and 2018, outstanding stock options and warrants to purchase shares of common stock in an aggregate of approximately 447,000 and 272,000, respectively, have been excluded from the calculation of diluted net income per share as all such securities were anti-dilutive. For the six months ended June 30, 2019 and 2018, outstanding stock options and warrants to purchase shares of common stock in an aggregate of approximately 424,000, and 287,000, respectively, have been excluded from the calculation of diluted income per share as all such securities were anti-dilutive.

Finance Receivables

Finance Receivables	6 Months Ended
	Jun. 30, 2019
Receivables [Abstract]
Finance Receivables	Note 3. Finance Receivables, Net Finance receivables are reported at their determined principal balances net of any unearned income, cumulative charge-offs and unamortized deferred fees and costs. Unearned income and deferred fees and costs are amortized to interest income based on all cash flows expected using the effective interest method. As of June 30, 2019, the Company had a provision for credit loss allowance of $6.8 million. Of the total $6.8 million, $1.2 million and $0.6 million are associated with the Company’s Cambia® and Besivance® royalties, respectively. The remaining $5.0 million is related to the ABT Molecular Imaging, Inc., now known as Best ABT, Inc. (“Best”), second lien term loan that was recognized in order to reflect the Best royalty at its estimated fair value of $5.8 million. The carrying values of finance receivables are as follows (in thousands): Portfolio June 30, December 31, Term loans $ 142,998 $ 136,379 Royalty purchases 32,946 36,410 Total before allowance for credit losses 175,944 172,789 Allowance for credit losses (6,788 ) (6,179 ) Total carrying value $ 169,156 $ 166,610 The following table presents nonaccrual and performing finance receivables by portfolio segment, net of credit loss allowance (in thousands): June 30, 2019 December 31, 2018 Nonaccrual Performing Total Nonaccrual Performing Total Term loans $ 8,337 $ 134,661 $ 142,998 $ 8,337 $ 128,042 $ 136,379 Royalty purchases, net of credit loss allowance 9,303 16,855 26,158 5,784 24,447 30,231 Total carrying value $ 17,640 $ 151,516 $ 169,156 $ 14,121 $ 152,489 $ 166,610 As of June 30, 2019, the Company had three finance receivables in nonaccrual status: (a) the term loan to B&D Dental Corporation (“B&D”), with a net carrying value of $8.3 million (b) the Best royalty, with a net carrying value of $5.8 million, and (c) the Tissue Regeneration Therapeutics, Inc. (“TRT”) royalty, with a net carrying value of $3.6 million. As of December 31, 2018, the Company had two finance receivables in nonaccrual status: (a) the term loan to B&D, with a net carrying value of $8.3 million, and (b) the Best royalty, with a net carrying value of $5.8 million. Although in nonaccrual status, neither the term loan nor the royalties were considered impaired as of June 30, 2019. The Company collected $33,000 on one of its nonaccrual royalties during the six months ended June 30, 2019. Besivance On April 2, 2013, the Company purchased an effective 2.4 percent royalty on sales of Besivance® from InSite Vision for $6.0 million. Besivance is marketed by Bausch & Lomb, formerly known as Valeant Pharmaceuticals. Sales performance of Besivance® has weakened primarily due to substantial declines in prescription volumes, which in conjunction with elevated sales chargebacks and various rebates (gross sales to net sales deductions), has resulted in material reductions in the product’s net sales and associated royalties payable to the Company. During the three months ended March 31, 2019, the Company reduced its expectations for future royalty receipts and recognized an allowance for credit loss on the royalty purchase of $0.6 million. TRT On June 13, 2013, the Company purchased royalties from TRT related to its technology licenses in the family cord banking services sector for $2.0 million, and on October 20, 2014, funded an additional $1.25 million upon the achievement of royalty receipts-based milestones. During the quarter ended March 31, 2016, royalty payments from the primary U.S. licensee ended as a result of the licensee terminating a technology license. SWK and TRT continue to evaluate both options in regard to enforcing TRT’s intellectual property rights against this licensee, as well as seeking additional U.S. licensees. TRT’s Canadian licensee continues to pay royalties. SWK is in discussions with TRT to restructure the purchase agreement. Given uncertainties regarding the outcome of the negotiations and the ultimate timing of cash flows related to the U.S. intellectual property, SWK has placed the TRT royalty on non-accrual status, although does not consider it is impaired. SWK evaluated several factors in this determination, including input from intellectual property counsel regarding the strength of the related intellectual property and continued receipt of Canadian licensee royalty payments.

Marketable Investments

Marketable Investments	6 Months Ended
	Jun. 30, 2019
Investments, Debt and Equity Securities [Abstract]
Marketable Investments	Note 4. Marketable Investments Investments in marketable securities at June 30, 2019 and December 31, 2018 consist of the following (in thousands): June 30, December 31, Corporate debt securities $ 498 $ 532 The amortized cost basis amounts, gross unrealized holding gains, gross unrealized holding losses and fair values of available-for-sale debt securities as of June 30, 2019 and December 31, 2018, are as follows (in thousands): June 30, 2019 Amortized Gross Gross Fair Value Corporate debt securities $ 498 $ — $ — $ 498 December 31, 2018 Amortized Gross Gross Fair Value Corporate debt securities $ 532 $ — $ — $ 532 The following table presents unrealized net losses on equity securities as prescribed by ASC 321, “Investment - Equity Securities.” ASU 2016-01, “Recognition and Measurement of Financial Assets and Financial Liabilities,” was adopted on January 1, 2018, at which time a cumulative effect adjustment of $213,000 was recorded to reclassify the amount of accumulated unrealized gains related to equity securities from accumulated other comprehensive income to retained earnings (in thousands): Three Months Ended Six Months Ended 2019 2018 2019 2018 Unrealized net loss on equity securities reflected in the Unaudited Condensed Consolidated Statements of Income $ — $ (541 ) $ — $ (664 ) Equity Securities The Company did not have any investments in equity securities as of June 30, 2019. As of June 30, 2018, the Company’s equity securities included shares of Cancer Genetics and Hooper Holmes common stock, which were sold and written off, respectively, during the year ended December 31, 2018. Debt Securities On July 9, 2013, the Company entered into a note purchase agreement to purchase, at par, $3.0 million of a total of $100.0 million aggregate principal amount of senior secured notes due in November 2026. The agreement allows the first interest payment date to include paid-in-kind notes for any cash shortfall, of which the Company received $0.1 million on November 15, 2013. The notes are secured only by certain royalty and milestone payments associated with the sales of pharmaceutical products. The senior secured notes have been placed on non-accrual status as of June 30, 2016. Total cash collected during the six months ended June 30, 2019 was $34,000 which was credited to the notes’ carrying value. As of June 30, 2019, the notes are reflected at their estimated fair value of $498,000.

Revolving Credit Facility

Revolving Credit Facility	6 Months Ended
	Jun. 30, 2019
SWKHP Holdings LP [Member]
Revolving Credit Facility	Note 5. Revolving Credit Facility On June 29, 2018, the Company entered into a Loan and Security Agreement (the “Loan Agreement”) with State Bank and Trust Company as a lender and the administrative agent (“State Bank”) pursuant to which State Bank will provide the Company with up to a $20 million revolving senior secured credit facility, which the Company can draw down and repay until maturity, subject to borrowing base eligibility. The Loan Agreement matures on June 29, 2021. The Loan Agreement accrues interest at the Daily LIBOR Rate, with a floor of 1.00 percent, plus a 3.25 percent margin and principal is repayable in full at maturity. Interest is generally required to be paid monthly in arrears. The Loan Agreement requires the payment of an unused line fee of 0.50 percent, which will be recorded as interest expense. The Company paid $0.5 million in fees at closing, which have been capitalized as deferred financing costs and are being amortized on a straight-line basis over the term of the Loan Agreement. The Loan Agreement has an advance rate against the Company’s finance receivables portfolio, including 85 percent against senior first lien loans, 70 percent against second lien loans and 50 percent against royalty receivables, subject to certain eligibility requirements as defined in the Loan Agreement. The Loan Agreement contains certain affirmative and negative covenants including minimum asset coverage and minimum interest coverage ratios. During the six months ended June 30, 2019, the Company recognized $0.2 million of interest expense. As of June 30, 2019, no amount was outstanding under the Loan Agreement, and $20 million was available for borrowing.

Related Party Transactions

Related Party Transactions	6 Months Ended
	Jun. 30, 2019
Related Party Transactions [Abstract]
Related Party Transactions	Note 6. Related Party Transactions On September 6, 2013, in connection with entering into a credit facility, the Company issued warrants to an affiliate of a stockholder, Carlson Capital, L.P. (the “Stockholder”), for 100,000 shares of the Company’s common stock at a strike price of $13.88 per share. The warrants have a price anti-dilution mechanism that was triggered by the price that shares were sold by the Company in a rights offering in 2014, and as a result, the strike price of the warrants was reduced to $13.48 per share. Due to certain provisions within the warrant agreement, the warrants meet the definition of a derivative and do not qualify for a scope exception, as it is not considered indexed to the Company’s stock. As such, the warrants are reflected as a warrant liability in the unaudited condensed consolidated balance sheets. The Company recorded a nominal loss for the six months ended June 30, 2019. The Company determined the fair value using the Black-Scholes option pricing model with the following assumptions: June 30, December 31, Dividend rate — — Risk-free rate 1.9 % 2.5 % Expected life (years) 1.2 1.7 Expected volatility 27.1 % 18.6 % The changes on the value of the warrant liability during the six months ended June 30, 2019 were as follows (in thousands): Fair value – December 31, 2018 $ 13 Issuances — Changes in fair value 15 Fair value – June 30, 2019 $ 28

Commitments and Contingencies

Commitments and Contingencies	6 Months Ended
	Jun. 30, 2019
Commitments and Contingencies Disclosure [Abstract]
Commitments and Contingencies	Note 7. Commitments and Contingencies As of June 30, 2019, the Company’s unfunded commitments were as follows (in millions): 4Web, Inc. $ 3.0 Aimmune Therapeutics, Inc. 3.8 Harrow Pharmaceuticals, Inc. 3.1 Solsys Systems, LLC 7.5 Total unfunded commitments $ 17.4 All unfunded commitments are contingent upon reaching an established revenue threshold or other performance metrics on or before a specified date or period of time per the terms of the royalty purchase or credit agreements, and in the case of loan transactions, are only subject to being advanced as long as an event of default does not exist. The unfunded commitment to Solsys Systems, LLC (“Solsys”) includes $2.5 million available upon Solsys raising at least $4.0 million of equity capital, and $5.0 million available upon consummation of the sale of Solsys to Misonix, Inc., which sale remains subject to certain conditions, including approval by the shareholders of Misonix, Inc.

Stockholders' Equity

Stockholders' Equity	6 Months Ended
	Jun. 30, 2019
Stockholders' Equity Note [Abstract]
Stockholders' Equity	Note 8. Stockholders’ Equity Stock Compensation Plans During the six months ended June 30, 2019 and 2018, the Company’s Board of Directors (the “Board”) approved compensation for Board services by granting 5,725 and 10,493 shares, respectively, of common stock as compensation for the non-employee directors. During both the six months ended June 30, 2019 and 2018, the Company recorded approximately $0.1 million in Board stock-based compensation expense. The aggregate stock-based compensation expense, including the quarterly Board grants, recognized by the Company for both of the six months ended June 30, 2019 and 2018 was $0.2 million and $0.1 million, respectively. The Company’s Chief Executive Officer, (“CEO”) received a grant of options to acquire up to 75,000 shares of the Company’s common stock, effective as of January 28, 2019. The options have a per-share exercise price of $12.50. The options are subject to vesting in equal annual installments over a three-year period based on the CEO’s continued employment with the Company. The options are subject to accelerated vesting upon a termination of the CEO’s employment if the CEO’s employment is terminated by the CEO for “Good Reason” as defined in the CEO’s employment agreement effective as of January 1, 2019. Furthermore, the 2012 and 2014 options received by the CEO were amended to extend the expiration dates to December 31, 2021. The options are forfeited and of no force and effect to the extent the options have not vested or become exercisable on or before December 31, 2021. The CEO also received a restricted stock award of 37,500 shares of restricted stock, subject to terms and conditions of the award agreement and the 2010 Stock Incentive Plan. The restricted stock is subject to vesting in equal annual installments over a three-year period but only to the extent the CEO is employed by or performing services for the Company. However, the restricted stock shall vest upon the CEO’s death, “Disability” and “Good Reason,” as defined in the Employment Agreement between the Company and the CEO effective January 1, 2019. On December 21, 2018, the Board of Directors of the Company authorized a stock repurchase program, which is described in Part II, Item 2 under Unregistered Sales of Equity Securities and Use of Proceeds

Fair Value Measurements

Fair Value Measurements	6 Months Ended
	Jun. 30, 2019
Fair Value Disclosures [Abstract]
Fair Value Measurements	Note 9. Fair Value Measurements The Company measures and reports certain financial and non-financial assets and liabilities on a fair value basis. Fair value is the price that would be received to sell an asset or paid to transfer a liability in an orderly transaction between market participants at the measurement date (exit price). GAAP specifies a three-level hierarchy that is used when measuring and disclosing fair value. The fair value hierarchy gives the highest priority to quoted prices available in active markets (i.e., observable inputs) and the lowest priority to data lacking transparency (i.e., unobservable inputs). An instrument’s categorization within the fair value hierarchy is based on the lowest level of significant input to its valuation. The following is a description of the three hierarchy levels. Level 1 Unadjusted quoted prices in active markets that are accessible at the measurement date for identical, unrestricted assets or liabilities. Active markets are considered to be those in which transactions for the assets or liabilities occur in sufficient frequency and volume to provide pricing information on an ongoing basis. Level 2 Quoted prices in markets that are not active, or inputs which are observable, either directly or indirectly, for substantially the full term of the asset or liability. This category includes quoted prices for similar assets or liabilities in active markets and quoted prices for identical or similar assets or liabilities in inactive markets. Level 3 Unobservable inputs are not corroborated by market data. This category is comprised of financial and non-financial assets and liabilities whose fair value is estimated based on internally developed models or methodologies using significant inputs that are generally less readily observable from objective sources. Transfers into or out of any hierarchy level are recognized at the end of the reporting period in which the transfers occurred. There were no transfers between any levels during the six months ended June 30, 2019. The following information is provided to help readers gain an understanding of the relationship between amounts reported in the accompanying unaudited condensed consolidated financial statements and the related market or fair value. The disclosures include financial instruments and derivative financial instruments, other than investment in affiliates. Following are descriptions of the valuation methodologies used to measure material assets and liabilities at fair value and details of the valuation models, key inputs to those models and significant assumptions utilized. Cash and cash equivalents The carrying amounts reported in the balance sheet for cash and cash equivalents approximate those assets’ fair values. Equity Securities Certain common equity securities are reported at fair value utilizing Level 1 inputs (exchange quoted prices). Finance Receivables The fair values of finance receivables are estimated using discounted cash flow analyses, using market rates at the balance sheet date that reflect the credit and interest rate-risk inherent in the finance receivables. Projected future cash flows are calculated based upon contractual maturity or call dates, projected repayments and prepayments of principal. These receivables are classified as Level 3. Finance receivables are not measured at fair value on a recurring basis, but estimates of fair value are reflected below. Marketable Investments and Derivative Securities Marketable Investments If active market prices are available, fair value measurement is based on quoted active market prices and, accordingly, these securities would be classified as Level 1. If active market prices are not available, fair value measurement is based on observable inputs other than quoted prices included within Level 1, such as prices for similar assets or broker quotes utilizing observable inputs, and accordingly these securities would be classified as Level 2. If market prices are not available and there are no observable inputs, then fair value would be estimated by using valuation models including discounted cash flow methodologies, commonly used option-pricing models and broker quotes. Such securities would be classified as Level 3, if the valuation models and broker quotes are based on inputs that are unobservable in the market. If fair value is based on broker quotes, the Company checks the validity of received prices based on comparison to prices of other similar assets and market data such as relevant bench mark indices. Available-for-sale securities are measured at fair value on a recurring basis, while securities with no readily available fair market value are not, but estimates of fair value are reflected below. Derivative Securities For exchange-traded derivatives, fair value is based on quoted market prices, and accordingly, would be classified as Level 1. For non-exchange traded derivatives, fair value is based on option pricing models and are classified as Level 3. The following table presents financial assets and liabilities measured at fair value on a recurring basis as of June 30, 2019 (in thousands): Total Quoted Prices Significant Significant Financial Assets: Warrant assets $ 3,993 $ — $ — $ 3,993 Corporate debt securities 498 — — 498 Financial Liabilities: Warrant liability $ 28 $ — $ — $ 28 The following table presents financial assets and liabilities measured at fair value on a recurring basis as of December 31, 2018 (in thousands): Total Quoted Prices Significant Significant Financial Assets: Warrant assets $ 2,777 $ — $ — $ 2,777 Corporate debt securities 532 — — 532 Financial Liabilities: Warrant liability $ 13 $ — $ — $ 13 The changes on the value of the warrant assets during the six months ended June 30, 2019 were as follows (in thousands): Fair value – December 31, 2018 $ 2,777 Issued 195 Canceled — Change in fair value 1,021 Fair value – June 30, 2019 $ 3,993 The Company holds warrants issued to the Company in conjunction with certain term loan investments. These warrants meet the definition of a derivative and are included in the unaudited condensed consolidated balance sheets. The fair values for warrants outstanding, which do not have a readily determinable value, are measured using the Black-Scholes option pricing model. The following ranges of assumptions were used in the models to determine fair value: June 30, 2019 December 31, 2018 Dividend rate range — — Risk-free rate range 1.8% to 1.9 % 2.5% to 2.6 % Expected life (years) range 4.3 to 7.9 4.8 to 7.9 Expected volatility range 69.4% to 89.9 % 67.6% to 101.8 % As of June 30, 2019 and December 31, 2018, the Company had two royalties, Besivance® and Cambia®, that were deemed to be impaired based on reductions in carrying values in prior periods. The following table presents these royalties measured at fair value on a nonrecurring basis as of June 30, 2019 and December 31, 2018 (in thousands): Total Quoted Prices Significant Significant June 30, 2019 Impaired royalties $ 6,762 $ — $ — $ 6,762 December 31, 2018 Impaired royalties $ 8,227 $ — $ — $ 8,227 There were no liabilities measured at fair value on a nonrecurring basis as of June 30, 2019 and December 31, 2018. The following information is provided to help readers gain an understanding of the relationship between amounts reported in the accompanying unaudited condensed consolidated financial statements and the related market or fair value. The disclosures include financial instruments and derivative financial instruments. As of June 30, 2019 (in thousands): Carry Value Fair Value Level 1 Level 2 Level 3 Financial Assets Cash and cash equivalents $ 27,373 $ 27,373 $ 27,373 $ — $ — Finance receivables 169,156 169,156 — — 169,156 Marketable investments 498 498 — — 498 Warrant assets 3,993 3,993 — — 3,993 Financial Liabilities Warrant liability $ 28 $ 28 $ — $ — $ 28 As of December 31, 2018 (in thousands): Carry Value Fair Value Level 1 Level 2 Level 3 Financial Assets Cash and cash equivalents $ 20,227 $ 20,227 $ 20,227 $ — $ — Finance receivables 166,610 166,610 — — 166,610 Marketable investments 532 532 — — 532 Warrant assets 2,777 2,777 — — 2,777 Financial Liabilities Warrant liability $ 13 $ 13 $ — $ — $ 13

SWK Holdings Corporation and _2

SWK Holdings Corporation and Summary of Significant Accounting Policies (Policies)	6 Months Ended
	Jun. 30, 2019
Accounting Policies [Abstract]
Nature of Operations	Nature of Operations SWK Holdings Corporation (the “Company”) was incorporated in July 1996 in California and reincorporated in Delaware in September 1999. In July 2012, the Company commenced its strategy of building a specialty finance and asset management business. The Company’s strategy is to be a leading healthcare capital provider by offering sophisticated, customized financing solutions to a broad range of life science companies, institutions and inventors. The Company is primarily focused on monetizing cash flow streams derived from commercial-stage products and related intellectual property through royalty purchases and financings, as well as through the creation of synthetic revenue interests in commercialized products. The Company has been deploying its assets to earn interest, fees, and other income pursuant to this strategy, and the Company continues to identify and review financing and similar opportunities on an ongoing basis. In addition, through the Company’s wholly-owned subsidiary, SWK Advisors LLC, the Company provides non-discretionary investment advisory services to institutional clients in separately managed accounts to similarly invest in life science finance. SWK Advisors LLC is registered as an investment advisor with the Texas State Securities Board. The Company intends to fund transactions through its own working capital, and its revolving credit facility, as well as by building its asset management business by raising additional third-party capital to be invested alongside the Company’s capital. The Company fills a niche that it believes is underserved in the sub-$50 million transaction size. Since many of its competitors that provide longer term, non-traditional debt and/or royalty-related financing options have much greater financial resources than the Company, they tend to not focus on transaction sizes below $50 million as it is generally inefficient for them to do so. In addition, the Company does not believe that a sufficient number of other companies offer similar types of long-term financing options to fill the demand of the sub-$50 million market. As such, the Company believes it faces less competition from such investors in transactions that are less than $50 million. The Company has net operating loss carryforwards (“NOLs”) and believes that the ability to utilize these NOLs is an important and substantial asset. However, at this time, under current law, we do not anticipate that our life science business strategy will generate sufficient income to permit us to utilize all of our NOLs prior to their respective expiration dates. As such, it is possible that we might pursue additional strategies that we believe might result in our ability to utilize more of our NOLs. As of August 12, 2019, the Company and its partners have executed transactions with 35 different parties under its specialty finance strategy, funding an aggregate $516 million in various financial products across the life science sector. The Company’s portfolio includes senior and subordinated debt backed by royalties and synthetic royalties paid by companies in the life science sector, and purchased royalties generated by sales of life science products and related intellectual property. The Company is headquartered in Dallas, Texas.
Basis of Presentation and Principles of Consolidation	Basis of Presentation and Principles of Consolidation The Company’s consolidated financial statements are prepared in accordance with accounting principles generally accepted in the U.S. (“GAAP”). The consolidated financial statements include the accounts of all subsidiaries and affiliates in which the Company holds a controlling financial interest as of the financial statement date. Normally a controlling financial interest reflects ownership of a majority of the voting interests. The Company consolidates a variable interest entity (“VIE”) when it possesses both the power to direct the activities of the VIE that most significantly impact its economic performance and the Company is either obligated to absorb the losses that could potentially be significant to the VIE or the Company holds the right to receive benefits from the VIE that could potentially be significant to the VIE, after elimination of intercompany accounts and transactions. The Company owns interests in various partnerships and limited liability companies, or LLCs. The Company consolidates its investments in these partnerships or LLCs, where the Company, as the general partner or managing member, exercises effective control, even though the Company’s ownership may be less than 50 percent, the related governing agreements provide the Company with broad powers, and the other parties do not participate in the management of the entities and do not effectively have the ability to remove the Company. The Company has reviewed each of the underlying agreements to determine if it has effective control. If circumstances change and it is determined this control does not exist, any such investment would be recorded using the equity method of accounting. Although this would change individual line items within the Company’s consolidated financial statements, it would have no effect on its operations and/or total stockholders’ equity attributable to the Company.
Unaudited Interim Financial Information	Unaudited Interim Financial Information The unaudited condensed consolidated financial statements have been prepared by the Company and reflect all normal, recurring adjustments that, in the opinion of management, are necessary for a fair presentation of the interim financial information. The results of operations for the interim periods presented are not necessarily indicative of the results to be expected for any subsequent quarter or for the year ending December 31, 2019. Certain information and footnote disclosures normally included in financial statements prepared in accordance with GAAP have been condensed or omitted under the rules and regulations of the Securities and Exchange Commission (“SEC”). These unaudited condensed consolidated financial statements and notes included herein should be read in conjunction with the audited consolidated financial statements and notes included in the Company’s Annual Report on Form 10-K for the year ended December 31, 2018, filed with the SEC on March 28, 2019.
Use of Estimates	Use of Estimates The preparation of the Company’s consolidated financial statements in conformity with GAAP requires the Company to make estimates and assumptions that affect the reported amounts of assets and liabilities at the date of the consolidated financial statements and the reported amounts of revenues and expenses during the reporting period. Significant estimates and assumptions are required in the determination of revenue recognition, stock-based compensation, impairment of financing receivables and long-lived assets, valuation of warrants, income taxes and contingencies and litigation, among others. Some of these judgments can be subjective and complex, and consequently, actual results may differ from these estimates. The Company’s estimates often are based on complex judgments, probabilities and assumptions that it believes to be reasonable but that are inherently uncertain and unpredictable. For any given individual estimate or assumption made by the Company, there may also be other estimates or assumptions that are reasonable. The Company regularly evaluates its estimates and assumptions using historical experience and other factors, including the economic environment. As future events and their effects cannot be determined with precision, the Company’s estimates and assumptions may prove to be incomplete or inaccurate, or unanticipated events and circumstances may occur that might cause changes to those estimates and assumptions. Market conditions, such as illiquid credit markets, volatile equity markets, and economic downturns, can increase the uncertainty already inherent in the Company’s estimates and assumptions. The Company adjusts its estimates and assumptions when facts and circumstances indicate the need for change. Those changes generally will be reflected in our consolidated financial statements on a prospective basis unless they are required to be treated retrospectively under the relevant accounting standard. It is possible that other professionals, applying reasonable judgment to the same facts and circumstances, could develop and support a range of alternative estimated amounts.
Recent Accounting Pronouncements	Recent Accounting Pronouncements In August 2018, the Financial Accounting Standards Board (“FASB”) issued Accounting Standards Update (“ASU”) No. 2018-13, “Fair Value Measurement (Topic 820) - Disclosure Framework - Changes to the Disclosure Requirements for Fair Value Measurement.” ASU 2018-13 updates the fair value measurement disclosure requirements by (i) eliminating certain requirements, including disclosure of the amount of and reasons for transfers between Level 1 and Level 2 of the fair value hierarchy, the policy for timing of transfers between levels and the valuation processes for Level 3 fair value measurements, (ii) modifying certain requirements, including clarifying that the measurement uncertainty disclosure is to communicate information about the uncertainty in measurement as of the reporting date and (iii) adding certain requirements, including disclosure of the changes in unrealized gains and losses for the period included in other comprehensive income for recurring Level 3 fair value measurements held at the end of the reporting period and the range and weighted average of significant unobservable inputs used to develop Level 3 fair value measurements. ASU 2018-13 is effective for fiscal years and interim periods within those years beginning after December 15, 2019, with early adoption permitted for any eliminated or modified disclosures. The Company is currently evaluating the new guidance but believes it will not have a material impact on its consolidated financial statements, as the Company has had no historical transfers between hierarchies. In June 2016, the FASB issued ASU No. 2016-13, “Financial Instruments - Credit Losses (Topic 326).” The new standard adds an impairment model, known as the current expected credit loss (“CECL”) model, that is based on expected losses rather than incurred losses. Under the new guidance, an entity recognizes as an allowance its estimate of expected credit losses, which the FASB believes will result in more timely recognition of losses. The ASU describes the impairment allowance as a valuation account that is deducted from the amortized cost basis of the financial asset(s) to present the net carrying value at the amount expected to be collected on the financial asset. Credit losses relating to available-for-sale debt securities should be measured in a manner similar to current GAAP; however, the amendments in this update require that credit losses be presented as an allowance rather than as a write-down, which will allow an entity the ability to record reversals of credit losses in current period net income. The amendments in this update are effective for fiscal years beginning after December 15, 2019, including interim periods within those fiscal years. An entity will apply the amendments in this update through a cumulative-effect adjustment to retained earnings as of the beginning of the first reporting period in which the guidance is effective (that is, a modified-retrospective approach). A prospective transition approach is required for debt securities for which an other-than-temporary impairment has been recognized before the effective date. The Company is currently evaluating the new guidance but believes it is likely to incur more upfront losses on its portfolio under the new CECL model. In February 2016, the FASB issued ASU No. 2016-02, Leases, as amended by subsequent ASUs (Topic 842). ASU 2016-02 supersedes guidance related to accounting for leases and provides for the recognition of lease assets and lease liabilities by lessees for those leases classified as operating leases under previous GAAP. The objective of the ASU is to establish the principles that lessees and lessors shall apply to report useful information to users of financial statements about the amount, timing and uncertainty of cash flows arising from a lease. ASU 2016-02 does not fundamentally change lessor accounting; however, some changes have been made to lessor accounting to conform and align that guidance with the lessee guidance and other areas within GAAP. The ASU is effective for fiscal years and interim periods within those years beginning after December 15, 2018. The Company adopted ASU 2016-02 on January 1, 2019 using the modified retrospective transition method, which permits application of the new standard on the adoption date as opposed to the earliest comparative period presented in the financial statements. In addition, the Company elected to use the available practical expedient package, and therefore did not reassess classification of its existing leases. The adoption of this ASU did not have a material impact on the Company’s consolidated financial statements.

Net Income per Share (Tables)

Net Income per Share (Tables)	6 Months Ended
	Jun. 30, 2019
Disclosure Net Income Per Share Tables Abstract
Schedule of earnings per share, basic and diluted	The following table shows the computation of basic and diluted net income per share for the following periods (in thousands, except per share amounts): Three Months Ended Six Months Ended 2019 2018 2019 2018 Numerator: Net income $ 4,327 $ 3,668 $ 10,886 $ 7,312 Denominator: Weighted-average shares outstanding 12,900 13,059 12,903 13,056 Effect of dilutive securities 3 4 3 4 Weighted-average diluted shares 12,903 13,063 12,906 13,060 Basic net income per share $ 0.34 $ 0.28 $ 0.84 $ 0.56 Diluted net income per share $ 0.34 $ 0.28 $ 0.84 $ 0.56

Finance Receivables (Tables)

Finance Receivables (Tables)	6 Months Ended
	Jun. 30, 2019
Receivables [Abstract]
Schedule of carrying value of finance receivables	Portfolio June 30, December 31, Term loans $ 142,998 $ 136,379 Royalty purchases 32,946 36,410 Total before allowance for credit losses 175,944 172,789 Allowance for credit losses (6,788 ) (6,179 ) Total carrying value $ 169,156 $ 166,610
Schedule of analysis of nonaccrual and performing loans by portfolio segment	The following table presents nonaccrual and performing finance receivables by portfolio segment, net of credit loss allowance (in thousands): June 30, 2019 December 31, 2018 Nonaccrual Performing Total Nonaccrual Performing Total Term loans $ 8,337 $ 134,661 $ 142,998 $ 8,337 $ 128,042 $ 136,379 Royalty purchases, net of credit loss allowance 9,303 16,855 26,158 5,784 24,447 30,231 Total carrying value $ 17,640 $ 151,516 $ 169,156 $ 14,121 $ 152,489 $ 166,610

Marketable Investments (Tables)

Marketable Investments (Tables)	6 Months Ended
	Jun. 30, 2019
Investments, Debt and Equity Securities [Abstract]
Schedule of marketable investments	Investments in marketable securities at June 30, 2019 and December 31, 2018 consist of the following (in thousands): June 30, December 31, Corporate debt securities $ 498 $ 532
Schedule of available-for-sale securities reconciliation	The amortized cost basis amounts, gross unrealized holding gains, gross unrealized holding losses and fair values of available-for-sale debt securities as of June 30, 2019 and December 31, 2018, are as follows (in thousands): June 30, 2019 Amortized Gross Gross Fair Value Corporate debt securities $ 498 $ — $ — $ 498 December 31, 2018 Amortized Gross Gross Fair Value Corporate debt securities $ 532 $ — $ — $ 532
Schedule of Proceeds from sales, gross unrealized gains and gross unrealized losses for available-for-sale securities	The following table presents unrealized net losses on equity securities as prescribed by ASC 321, “Investment - Equity Securities.” ASU 2016-01, “Recognition and Measurement of Financial Assets and Financial Liabilities,” was adopted on January 1, 2018, at which time a cumulative effect adjustment of $213,000 was recorded to reclassify the amount of accumulated unrealized gains related to equity securities from accumulated other comprehensive income to retained earnings (in thousands): Three Months Ended Six Months Ended 2019 2018 2019 2018 Unrealized net loss on equity securities reflected in the Unaudited Condensed Consolidated Statements of Income $ — $ (541 ) $ — $ (664 )

Related Party Transactions (Tab

Related Party Transactions (Tables)	6 Months Ended
	Jun. 30, 2019
Debt Disclosure [Abstract]
Schedule of assumptions used	The Company recorded a nominal loss for the six months ended June 30, 2019. The Company determined the fair value using the Black-Scholes option pricing model with the following assumptions: June 30, December 31, Dividend rate — — Risk-free rate 1.9 % 2.5 % Expected life (years) 1.2 1.7 Expected volatility 27.1 % 18.6 %
Schedule of value of the warrant liability	The changes on the value of the warrant liability during the six months ended June 30, 2019 were as follows (in thousands): Fair value – December 31, 2018 $ 13 Issuances — Changes in fair value 15 Fair value – June 30, 2019 $ 28

Commitments and Contingencies (

Commitments and Contingencies (Tables)	6 Months Ended
	Jun. 30, 2019
Commitments and Contingencies Disclosure [Abstract]
Schedule of Unfunded Commitments	As of June 30, 2019, the Company’s unfunded commitments were as follows (in millions): 4Web, Inc. $ 3.0 Aimmune Therapeutics, Inc. 3.8 Harrow Pharmaceuticals, Inc. 3.1 Solsys Systems, LLC 7.5 Total unfunded commitments $ 17.4

Fair Value Measurements (Tables

Fair Value Measurements (Tables)	6 Months Ended
	Jun. 30, 2019
Fair Value Disclosures [Abstract]
Schedule of fair value assets measured on recurring basis	The following table presents financial assets and liabilities measured at fair value on a recurring basis as of June 30, 2019 (in thousands): Total Quoted Prices Significant Significant Financial Assets: Warrant assets $ 3,993 $ — $ — $ 3,993 Corporate debt securities 498 — — 498 Financial Liabilities: Warrant liability $ 28 $ — $ — $ 28 The following table presents financial assets and liabilities measured at fair value on a recurring basis as of December 31, 2018 (in thousands): Total Quoted Prices Significant Significant Financial Assets: Warrant assets $ 2,777 $ — $ — $ 2,777 Corporate debt securities 532 — — 532 Financial Liabilities: Warrant liability $ 13 $ — $ — $ 13
Schedule of fair value assets measured on recurring basis unobservable input reconciliation	The changes on the value of the warrant assets during the six months ended June 30, 2019 were as follows (in thousands): Fair value – December 31, 2018 $ 2,777 Issued 195 Canceled — Change in fair value 1,021 Fair value – June 30, 2019 $ 3,993
Schedule of weighted average assumptions	The following ranges of assumptions were used in the models to determine fair value: June 30, 2019 December 31, 2018 Dividend rate range — — Risk-free rate range 1.8% to 1.9 % 2.5% to 2.6 % Expected life (years) range 4.3 to 7.9 4.8 to 7.9 Expected volatility range 69.4% to 89.9 % 67.6% to 101.8 %
Schedule of fair value assets and liabilities measured on nonrecurring basis	As of June 30, 2019 and December 31, 2018, the Company had two royalties, Besivance® and Cambia®, that were deemed to be impaired based on reductions in carrying values in prior periods. The following table presents these royalties measured at fair value on a nonrecurring basis as of June 30, 2019 and December 31, 2018 (in thousands): Total Quoted Prices Significant Significant June 30, 2019 Impaired royalties $ 6,762 $ — $ — $ 6,762 December 31, 2018 Impaired royalties $ 8,227 $ — $ — $ 8,227 There were no liabilities measured at fair value on a nonrecurring basis as of June 30, 2019 and December 31, 2018.
Schedule of fair value by balance sheet grouping	The following information is provided to help readers gain an understanding of the relationship between amounts reported in the accompanying unaudited condensed consolidated financial statements and the related market or fair value. The disclosures include financial instruments and derivative financial instruments. As of June 30, 2019 (in thousands): Carry Value Fair Value Level 1 Level 2 Level 3 Financial Assets Cash and cash equivalents $ 27,373 $ 27,373 $ 27,373 $ — $ — Finance receivables 169,156 169,156 — — 169,156 Marketable investments 498 498 — — 498 Warrant assets 3,993 3,993 — — 3,993 Financial Liabilities Warrant liability $ 28 $ 28 $ — $ — $ 28 As of December 31, 2018 (in thousands): Carry Value Fair Value Level 1 Level 2 Level 3 Financial Assets Cash and cash equivalents $ 20,227 $ 20,227 $ 20,227 $ — $ — Finance receivables 166,610 166,610 — — 166,610 Marketable investments 532 532 — — 532 Warrant assets 2,777 2,777 — — 2,777 Financial Liabilities Warrant liability $ 13 $ 13 $ — $ — $ 13

SWK Holdings Corporation and _3

SWK Holdings Corporation and Summary of Significant Accounting Policies (Details Narrative) $ in Thousands	Aug. 12, 2019USD ($)
Subsequent Event [Member] | Life Science [Member]
Business Combination, Aggregate Funding	$ 516,000

Net Income per Share (Details)

Net Income per Share (Details) - USD ($) $ / shares in Units, $ in Thousands	3 Months Ended				6 Months Ended
	Jun. 30, 2019	Mar. 31, 2019	Jun. 30, 2018	Mar. 31, 2018	Jun. 30, 2019	Jun. 30, 2018
Numerator:
Net income (loss) attributable to SWK Holdings Corporation Stockholders	$ 4,327	$ 6,559	$ 3,668	$ 3,644	$ 10,886	$ 7,312
Denominator:
Weighted-average shares outstanding	12,900,000		13,059,000		12,903,000	13,056,000
Effect of dilutive securities	3,000		4,000		3,000	4,000
Weighted-average diluted shares	12,903,000		13,063,000		12,906,000	13,060,000
Basic income (loss) per share attributable to SWK Holdings Corporation Stockholders	$ 0.34		$ 0.28		$ 0.84	$ 0.56
Diluted income (loss) per share attributable to SWK Holdings Corporation Stockholders	$ 0.34		$ 0.28		$ 0.84	$ 0.56
Antidilutive Securities Excluded from Computation of Earnings Per Share, Amount (in Shares)	447,000		272,000		424,000	287,000

Finance Receivables (Details)

Finance Receivables (Details) - USD ($) $ in Thousands	Jun. 30, 2019	Dec. 31, 2018
Portfolio
Total before allowance for credit losses	$ 175,944	$ 172,789
Allowance for credit losses	(6,788)	(6,179)
Total carrying value	169,156	166,610
Life Science Term Loans [Member]
Portfolio
Total before allowance for credit losses	142,998	136,379
Total carrying value	142,998	136,379
Life Science Royalty Purchases [Member]
Portfolio
Total before allowance for credit losses	32,946	36,410
Total carrying value	$ 26,158	$ 30,231

Finance Receivables (Details 2)

Finance Receivables (Details 2) - USD ($) $ in Thousands	Jun. 30, 2019	Dec. 31, 2018
Nonaccrual	$ 17,640	$ 14,121
Performing	151,516	152,489
Total	169,156	166,610
Life Science Term Loans [Member]
Nonaccrual	8,337	8,337
Performing	134,661	128,042
Total	142,998	136,379
Life Science Royalty Purchases [Member]
Nonaccrual	9,303	5,784
Performing	16,855	24,447
Total	$ 26,158	$ 30,231

Finance Receivables (Details Na

Finance Receivables (Details Narrative) - USD ($) $ in Thousands	6 Months Ended
	Jun. 30, 2019	Dec. 31, 2018	Apr. 02, 2013
Allowance for credit loss	$ 6,800
Besivance [Member]
Royalty Purchased on Sales, Percent			2.40%
Royalty Purchased on Sales, Amount			$ 6,000
ABT Molecular Imaging, Inc [Member]
Face amount	5,800	$ 5,800
ABT Molecular Imaging, Inc [Member] | First Lien Loan [Member]
Allowance for credit loss	5,000
ABT Molecular Imaging, Inc [Member] | Second Lien Loan [Member]
Allowance for credit loss	5,800
Cambia [Member]
Allowance for credit loss	1,200
Besivance [Member]
Allowance for credit loss	600
B&D Dental [Member]
Face amount	$ 8,300	$ 8,300

Marketable Investments (Details

Marketable Investments (Details) - USD ($) $ in Thousands	Jun. 30, 2019	Dec. 31, 2018
Investments, Debt and Equity Securities [Abstract]
Corporate debt securities	$ 498	$ 532

Marketable Investments (Detai_2

Marketable Investments (Details 2) - USD ($) $ in Thousands	3 Months Ended		6 Months Ended
	Jun. 30, 2019	Jun. 30, 2018	Jun. 30, 2019	Jun. 30, 2018	Dec. 31, 2018
Available for Sale Securities:
Amortized Cost					$ 532
Gross Unrealized Gains
Gross Unrealized Loss
Fair Value	$ 498		498		532
Equity investment losses reflected in the Consolidated Statements of Income		$ (541)		(664)
Corporate Debt Securities [Member]
Available for Sale Securities:
Amortized Cost	498		498		532
Gross Unrealized Gains
Gross Unrealized Loss
Fair Value	$ 498		$ 498		$ 532

Marketable Investments (Detai_3

Marketable Investments (Details Narrative) - USD ($) $ in Thousands	Nov. 15, 2013	Jun. 30, 2019	Jun. 30, 2018	Dec. 31, 2018	Jul. 09, 2013
Fair Value		$ 498		$ 532
Senior notes		498		$ 532
Paid-in-kind interest		805	$ 96
Agreement To Purchase Senior Secured Notes [Member]
Fair Value		498
Senior notes					$ 3,000
Paid-in-kind interest	$ 100
Cash collected from debt		$ 34
Tribute [Member] | Agreement To Purchase Senior Secured Notes [Member]
Senior notes					$ 100,000

Revolving Credit Facility (Deta

Revolving Credit Facility (Details Narrative) - USD ($) $ in Thousands	3 Months Ended		6 Months Ended
	Jun. 30, 2019	Jun. 30, 2018	Jun. 30, 2019	Jun. 30, 2018
Disclosure Revolving Credit Facility Details Narrative Abstract
Maximum Revolving Credit Available	$ 20,000		$ 20,000
Remaining Revolving Credit	20,000		20,000
Interest expense	$ 78	$ 2	$ 180	$ 2

Related Party Transactions (Det

Related Party Transactions (Details)	6 Months Ended	12 Months Ended
	Jun. 30, 2019	Dec. 31, 2018
Expected Dividend Rate [Member]
Dividend rate
Loan Credit Agreement [Member] | Expected Dividend Rate [Member]
Dividend rate
Loan Credit Agreement [Member] | Risk Free Interest Rate [Member]
Risk-free rate	1.90%	2.50%
Loan Credit Agreement [Member] | Expected Term [Member]
Expected life (years)	1 year 2 months 12 days	1 year 8 months 12 days
Loan Credit Agreement [Member] | Price Volatility [Member]
Expected volatility	27.10%	18.60%

Related Party Transactions (D_2

Related Party Transactions (Details 2) $ in Thousands	6 Months Ended
	Jun. 30, 2019USD ($)
Fair value at beginning	$ 13
Fair value at ending	28
Warrant Liability [Member]
Fair value at beginning	13
Issuances
Changes in fair value	15
Fair value at ending	$ 28

Related Party Transactions (D_3

Related Party Transactions (Details Narartive) - Delayed Draw [Member] - $ / shares	6 Months Ended
	Jun. 30, 2019	Sep. 06, 2013
Number of securities called by warrants or rights (in shares)		100,000
Exercise price of warrants or rights (in dollars per Share)		$ 13.88
Reduction in strike price	$ 13.48

Commitments and Contingencies_2

Commitments and Contingencies (Details) - USD ($) $ in Thousands	Jun. 30, 2019	Dec. 31, 2018
Total unfunded commitments
4Web, Inc. [Member]
Total unfunded commitments	3,000
Aimmune Therapeutics, Inc. [Member]
Total unfunded commitments	3,800
Harrow Pharmaceuticals, Inc. [Member]
Total unfunded commitments	3,100
Solsys Systems, LLC [Member]
Total unfunded commitments	7,500
Unfunded Loan Commitment [Member]
Total unfunded commitments	$ 17,400

Stockholders' Equity (Details N

Stockholders' Equity (Details Narrative) - USD ($) $ / shares in Units, $ in Thousands	1 Months Ended	6 Months Ended
	Jan. 28, 2019	Jun. 30, 2019	Jun. 30, 2018
Options exercise price, per share
Compensation for non-employee directors (in shares)		5,725	10,493
Allocated share-based compensation		$ 100	$ 100
Value of compensation for non-employee directors		$ 200	$ 200
Restricted Stock [Member] | Chief Executive Officer [Member]
Options granted	37,500
Stock Incentive Plan [Member] | Chief Executive Officer [Member]
Options granted	75,000
Options exercise price, per share	$ 12.50

Fair Value Measurements (Detail

Fair Value Measurements (Details) - USD ($) $ in Thousands	Jun. 30, 2019	Dec. 31, 2018
Financial Assets:
Warrant assets	$ 3,993	$ 2,777
Marketable investments	498	532
Financial Liabilities:
Warrant liability	28	13
Tribute Warrant [Member] | Fair Value, Inputs, Level 1 [Member]
Financial Assets:
Marketable investments
Tribute Warrant [Member] | Fair Value, Inputs, Level 3 [Member]
Financial Assets:
Warrant assets	3,993	2,777
Marketable investments	498	532
Financial Liabilities:
Warrant liability	28	13
Warrant Liability [Member]
Financial Liabilities:
Warrant liability	28	13
Marketable Securities [Member] | Tribute Warrant [Member]
Financial Assets:
Warrant assets	3,993	2,777
Marketable investments	498	532
Financial Liabilities:
Warrant liability	$ 28	$ 13

Fair Value Measurements (Deta_2

Fair Value Measurements (Details 2) $ in Thousands	6 Months Ended
	Jun. 30, 2019USD ($)
Fair value - December 31, 2017	$ 2,777
Fair value - June 30, 2018	3,993
Tribute Warrant [Member]
Fair value - December 31, 2017	2,777
Issuances	195
Canceled
Change in fair value	1,021
Fair value - June 30, 2018	$ 3,993

Fair Value Measurements (Deta_3

Fair Value Measurements (Details 3)	6 Months Ended	12 Months Ended
	Jun. 30, 2019	Dec. 31, 2018
Expected Dividend Rate [Member]
Dividend rate range
Risk Free Interest Rate [Member] | Minimum [Member]
Risk-free rate range	1.80%	2.50%
Risk Free Interest Rate [Member] | Maximum [Member]
Risk-free rate range	1.90%	2.60%
Expected Term [Member] | Minimum [Member]
Expected life (years) range	4 years 3 months 18 days	4 years 9 months 18 days
Expected Term [Member] | Maximum [Member]
Expected life (years) range	7 years 10 months 24 days	7 years 10 months 24 days
Price Volatility [Member] | Minimum [Member]
Expected volatility range	69.40%	67.60%
Price Volatility [Member] | Maximum [Member]
Expected volatility range	89.90%	101.80%

Fair Value Measurements (Deta_4

Fair Value Measurements (Details 4) - USD ($) $ in Thousands	Jun. 30, 2019	Dec. 31, 2018
Financial Assets:
Impaired loans	$ 3,993	$ 2,777
Fair Value, Inputs, Level 3 [Member]
Financial Assets:
Impaired loans	3,993	2,777
Tribute Warrant [Member]
Financial Assets:
Impaired loans	3,993	2,777
Tribute Warrant [Member] | Fair Value, Inputs, Level 3 [Member]
Financial Assets:
Impaired loans	6,762	8,227
Marketable Securities [Member] | Tribute Warrant [Member]
Financial Assets:
Impaired loans	$ 6,762	$ 8,227

Fair Value Measurements (Deta_5

Fair Value Measurements (Details 5) - USD ($) $ in Thousands	Jun. 30, 2019	Dec. 31, 2018	Jun. 30, 2018	Dec. 31, 2017
Financial Assets
Cash and cash equivalents	$ 27,373	$ 20,227	$ 21,281	$ 30,557
Cash and cash equivalents at fair value	27,373	20,227
Finance receivables	169,156	166,610
Finance receivables at fair value	169,156	166,610
Marketable investments	498	532
Marketable investments at fair value	498	532
Warrant assets	3,993	2,777
Warrant assets at fair value	3,993	2,777
Financial Liabilities
Warrant liability	28	13
Gross liability at fair value	28	13
Fair Value, Inputs, Level 1 [Member]
Financial Assets
Cash and cash equivalents at fair value	27,373	20,227
Fair Value, Inputs, Level 3 [Member]
Financial Assets
Finance receivables at fair value	169,156	166,610
Marketable investments at fair value	498	532
Warrant assets at fair value	3,993	2,777
Financial Liabilities
Gross liability at fair value	$ 28	$ 13